IGF-1 Peptide Is Rapidly Destroyed in the Gut, But Casein Protein Protects It

IGF-1 is degraded within minutes in the gut, but co-administration with casein protein significantly protects it from breakdown, suggesting a strategy for oral peptide delivery.

Xian, C J et al.·The Journal of endocrinology·1995·Moderate EvidenceAnimal StudyAnimal Study
RPEP-00348Animal StudyModerate Evidence1995RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

IGF-1 had a half-life of only 2 minutes in the duodenum and ileum, but casein protein significantly protected it from degradation in the gut.

Key Numbers

How They Did This

Researchers injected radiolabeled IGF-1 into ligated gut segments of fasted adult rats and measured its survival using three different assays (TCA precipitation, antibody binding, and receptor binding).

Why This Research Matters

This study addresses one of the biggest challenges in peptide therapeutics — oral bioavailability — and identified casein as a practical protective agent for gut-delivered peptides.

The Bigger Picture

Oral delivery of peptide therapeutics remains a major pharmaceutical challenge. This study's finding that a common milk protein can protect peptides from gut degradation opened a practical avenue for improving oral peptide bioavailability.

What This Study Doesn't Tell Us

Animal study using ligated gut segments, which don't fully represent normal gut transit. The 8.6 ng dose is much smaller than therapeutic doses. Protection by casein may vary with different peptides.

Questions This Raises

  • ?Could casein-based formulations make oral peptide therapeutics viable?
  • ?Does this protective effect extend to other peptides beyond IGF-1?

Trust & Context

Key Stat:
2-minute half-life IGF-1 was degraded with a half-life of just 2 minutes in the duodenum and ileum of fasted rats
Evidence Grade:
Moderate animal evidence with rigorous methodology using three independent assays. Directly relevant to peptide delivery challenges but not yet tested in humans.
Study Age:
Published in 1995, this study remains relevant to ongoing research into oral peptide delivery strategies.
Original Title:
Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein.
Published In:
The Journal of endocrinology, 146(2), 215-25 (1995)
Database ID:
RPEP-00348

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why can't most peptides be taken orally?

The gut contains powerful digestive enzymes that break down peptides within minutes. This study showed IGF-1 has a half-life of just 2 minutes in the small intestine, illustrating why oral peptide delivery is so challenging.

How does casein protect peptides?

Casein (a milk protein) likely acts as a competitive substrate — the gut's digestive enzymes attack the casein preferentially, giving the peptide more time to survive. It may also form protective complexes around the peptide.

Read More on RethinkPeptides

Cite This Study

RPEP-00348·https://rethinkpeptides.com/research/RPEP-00348

APA

Xian, C J; Shoubridge, C A; Read, L C. (1995). Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein.. The Journal of endocrinology, 146(2), 215-25.

MLA

Xian, C J, et al. "Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein.." The Journal of endocrinology, 1995.

RethinkPeptides

RethinkPeptides Research Database. "Degradation of IGF-I in the adult rat gastrointestinal tract..." RPEP-00348. Retrieved from https://rethinkpeptides.com/research/xian-1995-degradation-of-igfi-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.